Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells in Inflammatory Bowel Disease

Inflammatory Bowel Diseases Clinical Trial

— ADcSVF-IBD  

Official title:

Use of Autologous Adult Adipose-Derived Stem/Stromal Cells in Inflammatory Bowel Disease

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT02952131
• Other study ID #: RGV-GARM3
• Status: Enrolling by invitation
• Phase: Phase 1/Phase 2
• Start date: November 2016
• Est. completion date: June 19, 2025

Study information

• Verified date: August 2022
• Source: Healeon Medical Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Inflammatory Bowel Disease (IBD) is a group of inflammatory conditions of the small bowel and colon. Main types include Ulcerative Colitis and Crohn's Disease. Symptoms are often difficult to distinguish except for location and nature of changes. IBD complex arises with interaction of environmental, genetic factors, immunological responses, and chronic and recurring inflammation. Many factor appear as contributory, but no single set of issues appear to explain the process. Microbiota, intestinal wall granulation or breach, dietary, genetic predisposition all appear to factors. Treatment is often reactive or suppressive medications, neither of which appears to reverse the disease processes. This study explores the value of a complex group of adipose-derived stem/stromal cells (AD-cSVF) in the disease process.

Description:

IBD often presents clinically as abdominal pain, diarrhea (with and without blood), fever, weight loss, failure to thrive, and many related symptoms. Complications of the disorders may also include anemia, skin rashes, arthritis, severe chronic fatigue, and eye inflammatory changes. It is felt that IBD disorders may be caused by combination of environmental, immune, genetic, and bacterial factors. Results of these issues produce a chronic inflammatory disorder, in which the immune system attacks the gastrointestinal tract, perhaps directed by certain microbial antigens. The group appears not to be a pure autoimmune disease reaction, but may relate to a immunodeficiency state. There are no medications or surgical procedures that are known to cure the diseases. Most are aimed at reduction of symptoms, maintain remissions, and try to prevent relapses. Temporary anti-inflammatory medications may improve the acute process, followed by methotrexate or thiopurine to maintain remission states. Surgery appears important in cases of perforation, abscesses, obstructions, or cancer management. Actual occurrence is unknown, as there are more than Crohn's Disease and Ulcerative Colitis which appear related. It is estimated that more than 35,000 deaths were reported in 2010. Crohn's Disease alone appears to affect 3.2 per 1000 people in Europe and North America alone. The usual onset of symptoms may appear before actual diagnoses are made, with typical diagnoses occurring between 15-30 years of age. Lead by abdominal pain symptoms (usually lower right quadrant) and the recurrent periods of flare and remission. Many dietary, bacterial, antimicrobials, and environmental factors receive attention, some new interest in evaluating alternative therapeutic modalities to deal of issues of immune system. Use of the immune privileged cellular agents held within the AD-cSVF is proposed to help with the inflammatory contributors as well as the modulation of inflammation which favors chronic wound healing and avascular systems. Known to provide secretory antibiotic (ll-37) contributions, some thought of pro- and anti-microbials, may prove of value in those areas specifically. Cytokine and growth factors implications at the lesion sites remain to be poorly understood, but those experienced in biocellular regenerative therapies have experienced contributions to healing and prevention of recurrences of ulcerative skin lesions. Harvest of autologous of adipose-derived tissue stromal vascular fraction (AD-tSVF) is a proven rich resource of microvascular stem/stromal cell elements with well documented growth factor and cytokine contributors. With the advent of safe, measurable, and efficacious and reproducible numbers in a closed isolation environment, the ability to isolate and concentrate a cell-only product. This AD-cSVF is capable of reintroduction into patients, via a Normal Saline Solution, via parenteral route. This study is intended to evaluate the safety (adverse outcomes) and efficacy of using autologous cellular therapy in cases of IBD.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 100
• Est. completion date: June 19, 2025
• Est. primary completion date: August 14, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Patients, either sex 18 years and older with confirmed diagnosis of IBD
• Patients, either sex younger than 18 years upon approval of responsible parties and agreement of investigators
• Ability of patient to provide informed consent (or legal guardian)
• IBD diagnosed at least 6 months earlier to therapy using usual criteria
• Negative pregnancy test for women of childbearing age (menarche to menopause)

Exclusion Criteria:

• Mental incapacity that prevents adequate understanding of study and associate procedures and providing informed consent
• Severe IBD preventing tolerance of procedures needed
• Patients with impaired systemic condition, according to investigator judgment, needs immediate corticosteroid or surgical intervention
• Patients that fulfill criteria of cortico-dependency and in current treatment with corticosteroids
• Patients with history of colectomy
• Known history of alcohol, smoking dependence or additive substance abuse
• History related malignant disease - including patients participating in clinical trial with investigational drug within 6 months
• Patients with known history of allergies to any substance used in this protocol
• Pregnant or breastfeeding females
• Presence of severe concomitant disease, in investigators opinion threatens patient's well being or safety

Related Conditions & MeSH terms

• Inflammatory Bowel Diseases
• Intestinal Diseases

Intervention

Procedure:
• Lipoaspiration
Closed Syringe Harvesting Autologous Subdermal Fat
• AD-cSVF
Use of Centricyte 1000 to isolate adipose stem/stromal cells via centrifugation
• Normal Saline IV
Normal Saline IV containing AD-cSVF

Locations

Country	Name	City	State
United States	Regenevita LLC	Stevensville	Montana

Sponsors (2)

Lead Sponsor	Collaborator
Healeon Medical Inc	Terry, Glenn C., M.D.

Country where clinical trial is conducted

United States, 

References & Publications (40)

Aroniadis OC, Brandt LJ. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol. 2013 Jan;29(1):79-84. doi: 10.1097/MOG.0b013e32835a4b3e. Review. — View Citation

Axelrad JE, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol. 2016 May 28;22(20):4794-801. doi: 10.3748/wjg.v22.i20.4794. Review. — View Citation

Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007 May 12;369(9573):1627-40. Review. — View Citation

Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007 May 12;369(9573):1641-57. Review. — View Citation

Bennike T, Birkelund S, Stensballe A, Andersen V. Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies. World J Gastroenterol. 2014 Mar 28;20(12):3231-44. doi: 10.3748/wjg.v20.i12.3231. Review. — View Citation

Braat H, Peppelenbosch MP, Hommes DW. Immunology of Crohn's disease. Ann N Y Acad Sci. 2006 Aug;1072:135-54. Review. — View Citation

Broomé U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis. 2006 Feb;26(1):31-41. Review. — View Citation

Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis. 2010 Sep;16(9):1583-97. doi: 10.1002/ibd.21282. Review. — View Citation

Casanova JL, Abel L. Revisiting Crohn's disease as a primary immunodeficiency of macrophages. J Exp Med. 2009 Aug 31;206(9):1839-43. doi: 10.1084/jem.20091683. Epub 2009 Aug 17. Review. — View Citation

Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, Steinhoff M, Barbara G, Beck P, Bunnett NW, Sharkey KA, Ferraz JG, Shaffer E, Vergnolle N. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest. 2007 Mar;117(3):636-47. Epub 2007 Feb 15. — View Citation

Charlebois A, Rosenfeld G, Bressler B. The Impact of Dietary Interventions on the Symptoms of Inflammatory Bowel Disease: A Systematic Review. Crit Rev Food Sci Nutr. 2016 Jun 10;56(8):1370-8. doi: 10.1080/10408398.2012.760515. Review. — View Citation

Clevers H. Inflammatory bowel disease, stress, and the endoplasmic reticulum. N Engl J Med. 2009 Feb 12;360(7):726-7. doi: 10.1056/NEJMcibr0809591. — View Citation

Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2014 Dec;8(12):1569-81. doi: 10.1016/j.crohns.2014.08.006. Epub 2014 Sep 13. Review. — View Citation

Coskun M. Intestinal epithelium in inflammatory bowel disease. Front Med (Lausanne). 2014 Aug 25;1:24. doi: 10.3389/fmed.2014.00024. eCollection 2014. Review. — View Citation

Dave M, Mehta K, Luther J, Baruah A, Dietz AB, Faubion WA Jr. Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2015 Nov;21(11):2696-707. doi: 10.1097/MIB.0000000000000543. Review. — View Citation

Del Pinto R, Pietropaoli D, Chandar AK, Ferri C, Cominelli F. Association Between Inflammatory Bowel Disease and Vitamin D Deficiency: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2015 Nov;21(11):2708-17. doi: 10.1097/MIB.0000000000000546. Review. — View Citation

Dessein R, Chamaillard M, Danese S. Innate immunity in Crohn's disease: the reverse side of the medal. J Clin Gastroenterol. 2008 Sep;42 Suppl 3 Pt 1:S144-7. doi: 10.1097/MCG.0b013e3181662c90. Review. — View Citation

Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, Kastelein RA. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology. 2007 Jun;132(7):2359-70. Epub 2007 Apr 13. — View Citation

Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M. Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin Infect Dis. 2010 Feb 15;50(4):473-80. doi: 10.1086/649923. Review. — View Citation

Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol. 2014 Dec 9;7:473-87. doi: 10.2147/CEG.S27530. eCollection 2014. Review. — View Citation

Gilardi D, Fiorino G, Genua M, Allocca M, Danese S. Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine? Expert Rev Gastroenterol Hepatol. 2014 Sep;8(7):835-46. doi: 10.1586/17474124.2014.917954. Epub 2014 May 12. Review. — View Citation

Hara AK, Leighton JA, Heigh RI, Sharma VK, Silva AC, De Petris G, Hentz JG, Fleischer DE. Crohn disease of the small bowel: preliminary comparison among CT enterography, capsule endoscopy, small-bowel follow-through, and ileoscopy. Radiology. 2006 Jan;238(1):128-34. — View Citation

Henckaerts L, Figueroa C, Vermeire S, Sans M. The role of genetics in inflammatory bowel disease. Curr Drug Targets. 2008 May;9(5):361-8. Review. — View Citation

Joos S, Brinkhaus B, Maluche C, Maupai N, Kohnen R, Kraehmer N, Hahn EG, Schuppan D. Acupuncture and moxibustion in the treatment of active Crohn's disease: a randomized controlled study. Digestion. 2004;69(3):131-9. Epub 2004 Apr 26. — View Citation

Kristo I, Stift A, Bergmann M, Riss S. Surgical recurrence in Crohn's disease: Are we getting better? World J Gastroenterol. 2015 May 28;21(20):6097-100. doi: 10.3748/wjg.v21.i20.6097. Review. — View Citation

Lalande JD, Behr MA. Mycobacteria in Crohn's disease: how innate immune deficiency may result in chronic inflammation. Expert Rev Clin Immunol. 2010 Jul;6(4):633-41. doi: 10.1586/eci.10.29. Review. — View Citation

Langhorst J, Wulfert H, Lauche R, Klose P, Cramer H, Dobos GJ, Korzenik J. Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. J Crohns Colitis. 2015 Jan;9(1):86-106. doi: 10.1093/ecco-jcc/jju007. Epub 2014 Nov 28. Review. — View Citation

Mahadeva U, Martin JP, Patel NK, Price AB. Granulomatous ulcerative colitis: a re-appraisal of the mucosal granuloma in the distinction of Crohn's disease from ulcerative colitis. Histopathology. 2002 Jul;41(1):50-5. — View Citation

Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011 Jun 15;474(7351):298-306. doi: 10.1038/nature10208. Review. — View Citation

Marks DJ, Harbord MW, MacAllister R, Rahman FZ, Young J, Al-Lazikani B, Lees W, Novelli M, Bloom S, Segal AW. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet. 2006 Feb 25;367(9511):668-78. Erratum in: Lancet. 2007 Jul 28;370(9584):318. — View Citation

Marks DJ, Rahman FZ, Sewell GW, Segal AW. Crohn's disease: an immune deficiency state. Clin Rev Allergy Immunol. 2010 Feb;38(1):20-31. doi: 10.1007/s12016-009-8133-2. Review. — View Citation

Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012 Jan;142(1):46-54.e42; quiz e30. doi: 10.1053/j.gastro.2011.10.001. Epub 2011 Oct 14. Review. — View Citation

Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, Mitton S, Orchard T, Rutter M, Younge L, Lees C, Ho GT, Satsangi J, Bloom S; IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011 May;60(5):571-607. doi: 10.1136/gut.2010.224154. Review. — View Citation

Naser SA, Sagramsingh SR, Naser AS, Thanigachalam S. Mycobacterium avium subspecies paratuberculosis causes Crohn's disease in some inflammatory bowel disease patients. World J Gastroenterol. 2014 Jun 21;20(23):7403-15. doi: 10.3748/wjg.v20.i23.7403. Review. — View Citation

Smart HL, Mayberry JF, Atkinson M. Alternative medicine consultations and remedies in patients with the irritable bowel syndrome. Gut. 1986 Jul;27(7):826-8. — View Citation

Thomas S, Baumgart DC. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology. 2012 Feb;20(1):1-18. doi: 10.1007/s10787-011-0104-6. Epub 2011 Dec 20. Review. — View Citation

Trikudanathan G, Venkatesh PG, Navaneethan U. Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs. 2012 Dec 24;72(18):2333-49. doi: 10.2165/11638120-000000000-00000. Review. — View Citation

Walker MM, Murray JA. An update in the diagnosis of coeliac disease. Histopathology. 2011 Aug;59(2):166-79. doi: 10.1111/j.1365-2559.2010.03680.x. Epub 2010 Nov 3. Review. — View Citation

Wang GF, Ren JA, Liu S, Chen J, Gu GS, Wang XB, Fan CG, Li JS. Clinical characteristics of non-perianal fistulating Crohn's disease in China: a single-center experience of 184 cases. Chin Med J (Engl). 2012 Jul;125(14):2405-10. — View Citation

Yamamoto-Furusho JK, Korzenik JR. Crohn's disease: innate immunodeficiency? World J Gastroenterol. 2006 Nov 14;12(42):6751-5. Review. — View Citation

* Note: There are 40 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety: Inflammatory Bowel Disease	Inflammatory Bowel Disease to be addressed as occurrence or frequency of adverse event during study. Includes vital signs, complete blood count, and disease progression	12 months Evaluate Function and Adverse Events
Secondary	Efficacy: Quality of life index , Inflammatory Bowel Disease Questionnaire(IBD-QoL)	Comparison of response if it improves at least 30%	1 month, 6 month, 1 year
Secondary	Change from Baseline in C Reactive Protein (CRP)	Blood draw and laboratory measure of CRP as reflection of inflammatory baseline change	0, 2 weeks, 8 weeks, 12 weeks
Secondary	Efficacy: Change in Baseline of Modified Truelove-Witts Score (MTW)	Remission is considered if below 11, and response if it diminishes at least 30%	0, 4 weeks, 12 weeks
Secondary	Efficacy: Change in Baseline in Lichtiger Index	Remission considered if reaching 0 point, and response if the score diminishes from pretreatment level	0, 12 weeks, 6 months